scholarly journals Who Can Benefit from Adjuvant Transcatheter Arterial Chemoembolization after Surgical Resection of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S193
Author(s):  
L. Liang ◽  
C. Li ◽  
H. Xing ◽  
Y. Lau Wan ◽  
T.M. Pawlik ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Surgical Resection ◽  
Transcatheter Arterial Chemoembolization ◽  
Meta Analysis ◽  
Arterial Chemoembolization

scholarly journals Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma

2017 ◽  
Vol 22 (4) ◽  
pp. 883-891 ◽  
Author(s):  
Ya-Qing Zhang ◽  
Fei Zhao ◽  
Lei Song ◽  
Hong-Yun Gan ◽  
Xiao-Feng Xie
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Randomized Trials ◽  
Overall Response Rate ◽  
Transcatheter Arterial Chemoembolization ◽  
Response Rate ◽  
Meta Analysis ◽  
Randomized Controlled ◽  
Negative Conversion ◽  
Arterial Chemoembolization

Many studies have investigated the efficacy of Endostar combined with transcatheter arterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma (HCC). A systematic review was conducted to evaluate the efficacy of Endostar. PubMed, Embase, and other databases were searched, and meta-analysis was performed using RevMan 5.3 software. Nine studies, all of which were clinical randomized controlled trials, involving 411 participants were included. The overall response rate, disease control rate and α-fetoprotein negative conversion ratio, and the 6- and 12-month survival rate of HCC patients treated with combined Endostar and TACE were higher than those treated with TACE alone ( P < .01). Furthermore, the incidence of tumor progression was low after Endostar treatment ( P = .005). The incidence of adverse effects (leukocytopenia, liver function damage, and vomiting) was similar in Endostar with TACE and in TACE alone ( P > .05). However, large studies and more randomized trials are necessary to determine the effects of Endostar on HCC.

Sign in / Sign up

Export Citation Format

Share Document